Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-10-17

FDA Approved: NUPLAZID — Supplemental Application (Acadia Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved a supplemental application for NUPLAZID (pimavanserin tartrate) submitted by Acadia Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nuplazid (Pimavanserin)

Snippet

SUPPL AP for NUPLAZID (PIMAVANSERIN TARTRATE)